Compare CLPS & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | SABS |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 201.4M |
| IPO Year | 2017 | N/A |
| Metric | CLPS | SABS |
|---|---|---|
| Price | $1.06 | $4.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 14.8K | ★ 297.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.00 |
| 52 Week High | $1.88 | $6.60 |
| Indicator | CLPS | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 53.13 |
| Support Level | $0.90 | $3.43 |
| Resistance Level | $1.08 | $4.14 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.33 | 70.70 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.